ARS Pharmaceuticals Inc
NASDAQ:SPRY
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Price:
8.05
USD
-2.66%
Market Closed
Market Cap:
$799.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
ARS Pharmaceuticals Inc
NASDAQ:SPRY
|
US |
|
L
|
Lena Lighting SA
WSE:LEN
|
PL |
|
Oceanic Iron Ore Corp
XTSX:FEO
|
CA |
|
Granite Point Mortgage Trust Inc
NYSE:GPMT
|
US |
|
Oceanpal Inc
NASDAQ:OP
|
GR |
|
T Rowe Price Group Inc
NASDAQ:TROW
|
US |
|
Mink Therapeutics Inc
NASDAQ:INKT
|
US |
|
R
|
Rotem Shani Entrepreneurship and Investments Ltd
TASE:RTSN
|
IL |
Balance Sheet
Balance Sheet Decomposition
ARS Pharmaceuticals Inc
ARS Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
ARS Pharmaceuticals Inc
ARS Pharmaceuticals Inc
Balance Sheet
ARS Pharmaceuticals Inc
ARS Pharmaceuticals Inc
Currency: USD
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
20
|
10
|
387
|
254
|
211
|
71
|
51
|
41
|
|
| Cash Equivalents |
20
|
10
|
387
|
254
|
211
|
71
|
51
|
41
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
64
|
157
|
263
|
204
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
9
|
25
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
8
|
25
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
5
|
8
|
|
| Other Current Assets |
1
|
1
|
4
|
7
|
3
|
3
|
6
|
6
|
|
| Total Current Assets |
21
|
11
|
391
|
262
|
278
|
232
|
334
|
285
|
|
| PP&E Net |
6
|
5
|
4
|
7
|
1
|
1
|
1
|
2
|
|
| PP&E Gross |
6
|
5
|
4
|
7
|
1
|
1
|
1
|
0
|
|
| Accumulated Depreciation |
1
|
2
|
2
|
3
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
7
|
14
|
|
| Long-Term Investments |
0
|
0
|
0
|
65
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
1
|
1
|
0
|
0
|
3
|
1
|
8
|
26
|
|
| Total Assets |
28
N/A
|
16
-43%
|
395
+2 431%
|
334
-16%
|
281
-16%
|
233
-17%
|
351
+51%
|
328
-7%
|
|
| Liabilities | |||||||||
| Accounts Payable |
1
|
4
|
3
|
2
|
4
|
1
|
21
|
28
|
|
| Accrued Liabilities |
2
|
3
|
6
|
13
|
2
|
1
|
2
|
11
|
|
| Short-Term Debt |
3
|
12
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Total Current Liabilities |
5
|
18
|
10
|
15
|
5
|
2
|
23
|
39
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
96
|
|
| Other Liabilities |
4
|
3
|
2
|
5
|
3
|
0
|
71
|
78
|
|
| Total Liabilities |
9
N/A
|
21
+127%
|
12
-44%
|
20
+66%
|
9
-57%
|
2
-71%
|
94
+3 786%
|
213
+126%
|
|
| Equity | |||||||||
| Common Stock |
53
|
53
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
40
|
64
|
97
|
186
|
77
|
131
|
123
|
295
|
|
| Additional Paid In Capital |
5
|
5
|
480
|
500
|
349
|
362
|
380
|
409
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
18
N/A
|
6
N/A
|
383
N/A
|
314
-18%
|
273
-13%
|
231
-15%
|
257
+11%
|
114
-56%
|
|
| Total Liabilities & Equity |
28
N/A
|
16
-43%
|
395
+2 431%
|
334
-16%
|
281
-16%
|
233
-17%
|
351
+51%
|
328
-7%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
33
|
33
|
35
|
35
|
94
|
96
|
98
|
99
|
|
Switch to:
Switch to:
See Also
Discover More
